Pearl River Capital, LLC Blueprint Medicines Corp Transaction History

Pearl River Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$80.98 - $109.47 $200,506 - $271,047	-2,476 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$82.78 - $101.0 $204,963 - $250,076	2,476 New	2,476 $218,000
Q2 2020 Aug 10, 2020	SELL	$57.09 - $79.27 $5,709 - $7,927	-100 Closed	0 $0
Q1 2020 May 06, 2020	BUY	$48.11 - $82.22 $4,811 - $8,222	100 New	100 $6,000
Q1 2019 May 02, 2019	SELL	$48.7 - $86.6 $4,870 - $8,660	-100 Closed	0 $0
Q4 2018 Feb 08, 2019	BUY	$45.57 - $74.26 $4,557 - $7,426	100 New	100 $5,000

379

61.6M

1.6M

1.41M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.69B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Pearl River Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pearl River Capital, LLC with notifications on news.